MAYNE PHARMA GROUP LIMITED (MYX)
Share Price Analysis and Chart
Enter the company code or Name for stock analysis:

MYX - MAYNE PHARMA GROUP LIMITED
FNArena Sector :
Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Index: ASX300 | ALL-ORDS
FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
LAST PRICE | CHANGE +/- | CHANGE % | VOLUME |
---|---|---|---|
$0.30
25 May |
0.000 OPEN $0.29 |
0.000 HIGH $0.30 |
2,271,550 LOW $0.29 |
TARGET | |||||
|
|||||
Franking for last dividend paid out: 0% |
OTHER COMPANIES IN THE SAME SECTOR | |||
CUV . ACR . AHZ . CSL . IDT . IVX . MSB . RNO . OSL . TFC . TIS . KZA . AGH . FTT . PAR . ADO . PYC . RAC . RCE . ZNO . AVH . LGP . SPL . ARX . AFP . 1AD . TLX . PNV . MVP . BNO . NXS . GSS . EOF . NEU . PAL . PBP . BOT . IMU . MDC . IMM . PXS . HXL . MXC . OPT . ANP . |
FNARENA'S MARKET CONSENSUS FORECASTS
Title | FY20 Actual |
FY21 Actual |
FY22 Forecast |
FY23 Forecast |
---|---|---|---|---|
EPS (cps) | xxx | - 13.3 | - 2.5 | xxx |
DPS (cps) | xxx | 0.0 | 0.0 | xxx |
EPS Growth | xxx | N/A | N/A | xxx |
DPS Growth | xxx | N/A | N/A | xxx |
PE Ratio | xxx | N/A | N/A | xxx |
Dividend Yield | xxx | N/A | 0.0% | xxx |
Div Pay Ratio(%) | xxx | N/A | N/A | xxx |
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2022 FactSet UK Limited. All rights reserved
Title | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
---|---|---|---|---|---|---|
EPS Basic | xxx | xxx | xxx | xxx | xxx | -13.3 |
DPS All | xxx | xxx | xxx | xxx | xxx | 0.0 |
Sales/Revenue | xxx | xxx | xxx | xxx | xxx | 400.8 M |
Book Value Per Share | xxx | xxx | xxx | xxx | xxx | 43.5 |
Net Operating Cash Flow | xxx | xxx | xxx | xxx | xxx | 47.3 M |
Net Profit Margin | xxx | xxx | xxx | xxx | xxx | -52.00 % |
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin
Title | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
---|---|---|---|---|---|---|
Return on Capital Employed | xxx | xxx | xxx | xxx | xxx | -23.08 % |
Return on Invested Capital | xxx | xxx | xxx | xxx | xxx | -17.00 % |
Return on Assets | xxx | xxx | xxx | xxx | xxx | -12.55 % |
Return on Equity | xxx | xxx | xxx | xxx | xxx | -23.08 % |
Return on Total Capital | xxx | xxx | xxx | xxx | xxx | 0.11 % |
Free Cash Flow ex dividends | xxx | xxx | xxx | xxx | xxx | 30.2 M |
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends
This is work in progress. Bear with us. It'll be amazing.
EXPERT VIEWS
Display All Commentary
Sentiment Indicator
No. Of Recommendations
MYX STOCK CHART

FNArena News on MYX
1 |
Australian Broker Call *Extra* Edition – Apr 07, 2022Apr 07 2022 - Daily Market Reports |
2 |
FNArena Corporate Results Monitor – 28-02-2022Feb 28 2022 - Australia |
3 |
Rudi’s View: February Results; Macro, Traps And OpportunitiesFeb 10 2022 - Rudi's View |
4 |
Australian Broker Call *Extra* Edition – Nov 26, 2021Nov 26 2021 - Daily Market Reports |
5 |
Australian Broker Call *Extra* Edition – Sep 30, 2021Sep 30 2021 - Daily Market Reports |
Latest Pharmaceuticals & Biotech/Lifesciences News
1 |
CSL: Buy Trigger AheadApr 26 2022 - Technicals |
2 |
Why CSL Fell Sharply YesterdayDec 17 2021 - Australia |
3 |
Beating The Biotech BluesSep 14 2021 - International |
4 |
Uncertainty Prevails For CSLAug 19 2021 - Australia |
5 |
Flying High – Medicinal Marijuana In AustraliaJul 26 2021 - Australia |
6 |
Wesfarmers On Drugs?Jul 13 2021 - Australia |
7 |
Is CSL’s Plasma Recovery Now Priced In?Jun 23 2021 - Australia |
8 |
CSL: Buy The DipJun 22 2021 - Technicals |
9 |
CSL To Retest Its High?May 25 2021 - Technicals |
10 |
Treasure Chest: CSL Plasma At Turning Point?May 05 2021 - Treasure Chest |